Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Labopharm has named Mary Anne Heino as the new president of Angelini Labopharm and Jeffrey Dayno as the president of Labopharm USA.
Subscribe to our email newsletter
Before joining Labopharm, Heino held executive positions in a subsidiary of Johnson & Johnson, Centocor.
Prior to Centocor, Heino worked with Janssen Pharmaceuticals, also a subsidiary of Johnson & Johnson and held various leadership positions.
Dayno held senior executive roles at Merck followed by Cephalon, where he was the vice president of Medical Services.
Labopharm president and CEO James Howard-Tripp said as acting president of Angelini Labopharm, Mary Anne played an instrumental role in the commercial preparation for the US launch of Oleptro last August.
"Since joining Labopharm last year as chief medical officer, Jeff has demonstrated leadership across the organization and made significant contributions both to the launch of Oleptro and managing the clinical relationship with Angelini Labopharm," Howard-Tripp said.